Results 31 to 40 of about 129,511,766 (119)

Ibrutinib-associated alveolar hemorrhage and spontaneous hemothorax

open access: yesPolish Journal of Thoracic and Cardiovascular Surgery, 2022
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase of the Tec family, which plays an important role in the B-cell receptor signaling pathway [1].
Ismail Tombul   +5 more
doaj   +1 more source

Platelet CLEC‐2 and lung development

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2020
In this article, the State of the Art lecture “Platelet CLEC‐2 and Lung Development” presented at the ISTH congress 2019 is reviewed. During embryonic development, blood cells are often considered as porters of nutrition and oxygen but not as active ...
Katsue Suzuki‐Inoue, Nagaharu Tsukiji
doaj   +1 more source

Podoplanin: A potential therapeutic target for thrombotic diseases

open access: yesFrontiers in Neurology, 2023
As a specific lymphatic marker and a key ligand of C-type lectin-like receptor 2 (CLEC-2), podoplanin (Pdpn) is involved in various physiological and pathological processes such as growth and development, respiration, blood coagulation, lymphangiogenesis,
Yaqian Huang   +5 more
doaj   +1 more source

BACL is a novel brain-associated, non-NKC-encoded mammalian C-type lectin-like receptor of the CLEC2 family [PDF]

open access: yes, 2013
Natural Killer Gene Complex (NKC)–encoded C-type lectin-like receptors (CTLRs) are expressed on various immune cells including T cells, NK cells and myeloid cells and thereby contribute to the orchestration of cellular immune responses.
Mittelbronn, Michel Guy André   +15 more
core   +1 more source

sCLEC-2 (Soluble C-Type Lectin-like Receptor 2) as a New Diagnostic Marker of Platelet Activation in Colorectal Cancer Patients—A Preliminary Study

open access: yesDiagnostics
Background/Objectives: CLEC-2 (C-type lectin-like receptor 2), the newest discovered platelet receptor, is involved in platelet activation and aggregation, the inflammatory response, tumor growth, metastasis, and angiogenesis.
Violetta Dymicka-Piekarska   +7 more
doaj   +1 more source

TULA-2 Deficiency Enhances Platelet Functional Responses to CLEC-2 Agonists

open access: yesTH Open, 2018
Platelet activation is essential for hemostasis. Central to platelet activation are the signals transmitted through surface receptors such as glycoprotein VI, the protease-activated receptors, and C-type lectin-like receptor 2 (CLEC-2).
John C. Kostyak   +8 more
doaj   +1 more source

Decreased plasma level of C-type lectin-like receptor 2 (CLEC-2) in patients with breast cancer

open access: yesInternational Journal of Medical Sciences
Background: C-type lectin-like receptor 2 (CLEC-2) is involved in platelet activation, tumor metastasis, and vessel differentiation, but its role in breast cancer remains unclear. This study examined the association between clinical status and plasma levels of CLEC-2 in patients with breast cancer.
Chen, Chia-Chi   +10 more
openaire   +2 more sources

C-type lectin-like receptor 2: roles and drug target

open access: yesThrombosis Journal
C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively.
Lan Sun   +5 more
doaj   +1 more source

Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

open access: yesClinical and Applied Thrombosis/Hemostasis, 2022
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a
Ying Ji MD   +8 more
doaj   +1 more source

Activation of Platelet Caspase‐1 and P‐Selectin Over‐Expression in Sickle Cell Disease Patients: An Involvement of NLRP3 Inflammasome?

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 20, October 2026.
ABSTRACT Sickle cell disease (SCD) is characterized by hemolytic anaemia, painful vaso‐occlusive crises, and chronic inflammation resulting partly from platelet activation. It has been shown that platelets express the nucleotide‐binding domain leucine‐rich repeat containing protein 3 (NLRP3) and the apoptosis‐associated speck‐like protein containing a ...
Livia Claude   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy